

1 **General approach of causal mediation analysis with causally** 2 **ordered multiple mediators and survival outcome**

3 An-Shun Tai¹, Pei-Hsuan Lin¹, Yen-Tsung Huang², Sheng-Hsuan Lin^{1*}

4
5 1. Institute of Statistics, National Chiao Tung University, Hsin-Chu, Taiwan. 1001 University
6 Road, Hsinchu, Taiwan 300

7 2. Institute of Statistical Science, Academia Sinica, Taipei, Taiwan. Environmental Changes
8 Research Building, No.128, Academia Road, Section 2, Nankang, Taipei, Taiwan 11529

9 10 ***Corresponding author**

11 Sheng-Hsuan Lin, MD, ScD

12 Institute of Statistics, National Chiao Tung University, Hsin-Chu, Taiwan

13 1001 University Road,

14 Hsinchu, Taiwan 300

15 Cell: 886-3-5712121 ext 56822

16 E-mail: shenglin@stat.nctu.edu.tw

17 **Summary**

18 Causal mediation analysis with multiple mediators (causal multi-mediation analysis) is
19 critical in understanding why an intervention works, especially in medical research.
20 Deriving the path-specific effects (PSEs) of exposure on the outcome through a certain
21 set of mediators can detail the causal mechanism of interest. However, the existing
22 models of causal multi-mediation analysis are usually restricted to partial
23 decomposition, which can only evaluate the cumulative effect of several paths.
24 Moreover, the general form of PSEs for an arbitrary number of mediators has not been
25 proposed. In this study, we provide a generalized definition of PSE for partial
26 decomposition (partPSE) and for complete decomposition, which are extended to the
27 survival outcome. We apply the interventional analogues of PSE (iPSE) for complete
28 decomposition to address the difficulty of non-identifiability. Based on Aalen's additive
29 hazards model and Cox's proportional hazards model, we derive the generalized
30 analytic forms and illustrate asymptotic property for both iPSEs and partPSEs for
31 survival outcome. The simulation is conducted to evaluate the performance of
32 estimation in several scenarios. We apply the new methodology to investigate the
33 mechanism of methylation signals on mortality mediated through the expression of
34 three nested genes among lung cancer patients.

35

1 1. Introduction

2 Causal mediation analysis in the presence of multiple mediators (termed as “causal
3 multi-mediation analysis” throughout this article) is one of the most powerful methods
4 to investigate the detailed mechanism of a confirmed causal effect. To explicitly
5 describe the detailed compositions of this causal mechanism, Avin et al. proposed path-
6 specific effects (PSEs) based on a counterfactual framework to quantify pathways
7 comprised of mediators of interest (Avin, *et al.*, 2005). However, most PSEs cannot be
8 nonparametrically identified (Daniel, *et al.*, 2015). Several methods have been
9 proposed to address the difficulty of non-identifiability, which are summarized in
10 Figure 1. In settings with K mediators, we categorize the existing approaches into three
11 groups according to the number of paths to be decomposed: (1) Two-way
12 decomposition; (2) Partial decomposition; and (3) Complete decomposition. Two-way
13 decomposition treats all mediators as one unit and decomposes total effect (TE) into the
14 natural direct and indirect effects rather than detailed PSEs (Fasanelli, *et al.*, 2019;
15 VanderWeele and Vansteelandt, 2014). Partial decomposition decomposes natural
16 indirect effects into K (or $K+1$) paths through each distinct mediator, and can be further
17 categorized into three subgroups according to different assumptions of causal structure
18 among mediators: (2.1) partial parallel decomposition, (2.2) partial sequential
19 decomposition, and (2.3) partial unstructured decomposition. Specifically, partial
20 parallel decomposition assumes that the multiple mediators are not affected by each
21 other (Taguri, *et al.*, 2015; Wang, *et al.*, 2013). Partial sequential decomposition
22 assumes that mediators are causally ordered (Steen, *et al.*, 2017; Vanderweele, *et al.*,
23 2014). Partial unstructured decomposition does not assume the structure among
24 mediators and decomposes the joint indirect effect into K separate indirect effect
25 through each mediator and one indirect effect through the dependence among mediators
26 (Loh, *et al.*, 2019; Moreno-Betancur, *et al.*, 2019; Vansteelandt and Daniel, 2017).
27 However, the character of an undefined structure causes that partial unstructured
28 decomposition cannot explicitly identify the paths of interest in general, which leads to
29 the difficulty of interpreting the causal mechanism. Complete decomposition (also
30 termed full or finest decomposition) decomposes TE into all 2^K PSEs, most of which
31 are unidentified. Two choices are available: (3.1) sensitivity analysis approach and (3.2)
32 complete interventional approach. Sensitivity analysis approach evaluates the boundary
33 of PSE (Albert, *et al.*, 2019; Daniel, *et al.*, 2015), while interventional approach
34 proposed a randomized interventional analogues of PSE (iPSE) (Lin and VanderWeele,
35 2017). The typical interventional approach has been widely used for settings with one
36 mediator (Didelez, *et al.*, 2012; Geneletti, 2007; Vanderweele, *et al.*, 2014), time-
37 varying mediators (Lin, *et al.*, 2017; Lin, *et al.*, 2017; VanderWeele and Tchetgen

1 Tchetgen, 2017; Zheng and van der Laan, 2012), and multiple mediator with partial
2 decomposition (Moreno-Betancur, *et al.*, 2019; Vansteelandt and Daniel, 2017).

3 In terms of the survival framework, the method involving one mediator was first
4 proposed by Lange and Hansen based on additive hazard model (Lange and Hansen,
5 2011). VanderWeele extended Lange and Hansen’s approach using both the Cox’s
6 proportional hazards model and the accelerated failure time model with a rare disease
7 assumption (VanderWeele, 2011), while Tchetgen and Shpitser proposed a more general
8 semiparametric approach (Tchetgen and Shpitser, 2012). Several methods have been
9 proposed for scenarios with two or three causally ordered multiple mediators (Cho and
10 Huang, 2019; Fasanelli, *et al.*, 2019; Huang and Yang, 2017; Huang and Cai, 2015; Yu,
11 *et al.*, 2019). Although these studies specifically derived the analytic form of PSEs for
12 survival outcome, two issues have not been fully addressed yet. First, due to the
13 exponential increase in the number of PSEs along with the number of mediators, the
14 existing methods only allow a small number of mediators (Figure1). A general form of
15 PSE with an arbitrary number of mediators is necessary for a wide application in
16 general cases. Second, the existing approaches for survival outcome mainly focus on
17 partial decomposition which only estimates the cumulative effect of several paths. A
18 complete decomposition of each path is necessary for the comprehensive understanding
19 of the causal mechanism. Furthermore, the existing methods need to assume no time-
20 varying confounders, which restricts the utility of these methods on longitudinal data.

21 To address the issues mentioned above, this study proposes a generalized
22 framework for causal multi-mediation analysis via both partial sequential
23 decomposition and complete interventional approach, especially for the survival
24 outcome. For simplicity, we name partial sequential decomposition as partial
25 decomposition approach and name complete interventional approach as interventional
26 approach in the following paragraphs and sections. There are two contributions in this
27 study. First, we propose comprehensive definitions of partial decomposition and
28 interventional approaches, under which a generalized form of PSE with an arbitrary
29 number of mediators has been provided. Second, we extend partial decomposition and
30 interventional approaches into the context of survival analysis. We demonstrate the
31 mediation parameters of interest perform a g-formula while mediators are weighted by
32 a normally distributed variable when all mediators are continuous and normally
33 distributed. The parameters can be viewed as a general form of a series of previous
34 works in this topic (Cho and Huang, 2019; Huang and Yang, 2017; VanderWeele, 2011;
35 Yu, *et al.*, 2019).

36 The remainder of this paper is organized as follows. In Section 2, we introduce
37 notations and definition for causal multi-mediation analysis under partial

1 decomposition and interventional approaches for the setting with an arbitrary number
 2 of mediators and any types of outcomes. In Section 3, we derive the estimators in terms
 3 of survival analysis by using Aalen’s additive hazards model and Cox’s proportional
 4 hazards model. In Section 4, we demonstrate the asymptotic properties. In Section 5,
 5 we provide the simulation results in different scenarios to demonstrate the performance
 6 of estimation. In Section 6, we illustrate an application to investigate the mechanism of
 7 methylation signals on mortality through the transcriptional activity of several genes
 8 which are nested to each other. We discuss the strength and limitations in Section 7.

9 **2. Generalized framework of causal multi-mediation analysis**

10 In this section, we first provide the generalized definition of PSEs for any types of
 11 outcome variables. Since PSEs cannot be nonparametrically identified, interventional
 12 approach for completely decomposing all PSEs and partial decomposition approach
 13 without changing the PSE definition are used to address this issue. The corresponding
 14 identification processes and the required assumptions will also be demonstrated.

15 2.1. Notation, parameter of interest in ordered multiple mediators, and 16 difficulties

17 To simplify the notation, we denote $V_{(i_1, i_2)} = (V_{i_1}, V_{i_1+1}, \dots, V_{i_2})$ as a subvector
 18 of a vector V where i_1 and i_2 are two nonnegative integers satisfied $i_1 < i_2$; we
 19 further define $V_{(i_1, i_2)} = v_i$ for $i_1 = i_2 = i$, and $V_{(i_1, i_2)} =$ a null vector for $i_1 > i_2$.
 20 Furthermore, we use $V_{(1:K; -i)}$ to denote $(V_1, \dots, V_{i-1}, V_{i+1}, \dots, V_K)$. Let K denotes
 21 the number of mediators, A the exposure, $M = (M_{(1:K)})$ the causally ordered
 22 mediators, Y the outcome, C_0 the baseline confounders, and $C = (C_{(1:K)})$ the time-
 23 varying confounders. C_k represents the k -th confounders among the k -th mediator M_k
 24 and Y which occurs after and is potentially affected by M_{k-1} and the other previous
 25 variables for $k \in \{1, 2, \dots, K\}$. The causal relationship among all variables is illustrated
 26 by a directed acyclic graph (DAG) in Figure 2.

27 In the counterfactual framework, $Y(a, m_{(1:K)})$ represents the counterfactual
 28 value of Y suppose $(A, M_{(1:K)})$ is set to $(a, m_{(1:K)})$. Let $M_k(a, m_{(1, k-1)})$ be the
 29 counterfactual value of M_k suppose $(A, M_{(1, k-1)})$ is set to $(a, m_{(1, k-1)})$ for $k \in$
 30 $\{1, 2, \dots, K\}$ (Robins, 1986). Furthermore, we assume consistency (Pearl, 2009;
 31 VanderWeele and Vansteelandt, 2009; VanderWeele, 2009), under which $Y(a, m_{(1:K)})$
 32 is equal to the observed Y if $(A, M_{(1:K)})$ is equal to $(a, m_{(1:K)})$ and $M_k(a, m_{(1, k-1)})$
 33 is equal to the observed M_k if $(A, M_{(1, k-1)})$ is equal to $(a, m_{(1, k-1)})$ for $k \in$
 34 $\{1, 2, \dots, K\}$.

35 Since the number of PSEs increases exponentially ($= 2^K$) according to the
 36 involvement of $M_{(1:K)}$, a definition system is required for a generalized setting. We

1 propose a comprehensive coding system for notation simplification and define PSEs.

2 In the setting with K ordered mediators, a set of all paths is defined as

$$3 \quad L = \{ l_d = (I(M_1), \dots, I(M_K)) \mid$$

$$4 \quad d = \sum_{k=1}^K I(M_k) \times 2^{k-1} + 1, I(M_k) \in \{0,1\} \text{ for } k = 1, \dots, K \},$$

5 where $I(M_k) = 1$ represents the path l_d passing through the k -th mediator, M_k . For

6 simplicity, each path $l_d = (I(M_1), \dots, I(M_K))$ in L is numbered as d , which is an

7 integer converted by a one-to-one converted function (ξ), which is defined as

$$8 \quad \xi(I(M_1), \dots, I(M_K)) = \sum_{k=1}^K I(M_k) \times 2^{k-1} + 1. \text{ Each converted number (i.e. } d) \text{ is}$$

9 specifically mapped to one path. On the basis of these converted numbers, PSE can be

10 qualitatively defined as a function of the converted number as follows:

11 *Definition 1* (Qualitative definition of Path-Specific Effect, $PSE_K(d)$).

12 For K mediators, $PSE_K(d)$ represents the path-specific effect with respect to the path

13 $l_d = (I(M_1), \dots, I(M_K))$, where $d \in \{1, 2, 3, \dots, 2^K\}$ and $I(M_k) = 1$ represents the

14 path l_d passing through the k -th mediator, M_k .

15 In addition to the qualitative definition, the $PSE_K(d)$ is needed to be

16 quantitatively defined under counterfactual model. Before this, we must define

17 “iterative counterfactual mediators” and “multi-mediation parameter” as *Definition 2*

18 and *Definition 3*, respectively, for simplifying the notation.

19 *Definition 2* (Iterative counterfactual mediators, $M_k^*(a_{(1,2^{k-1})})$).

20 For $k = 1$, $M_1^*(a_1) \equiv M_1(a_1)$, which is the counterfactual value of M_1 suppose $A = a_1$.

21 For $k \in \{2, \dots, K\}$, let $M_k^*(a_{(1,2^{k-1})}) \equiv M_k(a_1, M_1^*(a_2), \dots, M_{k-1}^*(a_{(2^{k-2}+1, 2^{k-1})}))$, which is

22 the counterfactual value of M_k suppose $(A, M_{(1,k-1)})$ is set to

23 $(a_1, M_1^*(a_2), \dots, M_{k-1}^*(a_{(2^{k-2}+1, 2^{k-1})}))$. For any $k \in \{1, \dots, K\}$, M_k^* is a function of $a_{(1,2^{k-1})}$.

24 On the basis of *Definition 2*, we can further define multi-mediation parameter in a

25 general form as *Definition 3*.

26 *Definition 3*. (Multi-mediation parameter $\vartheta_K(a_{(1,2^K)}|W_t)$)

$$27 \quad \vartheta_K(a_{(1,2^K)}|W_t) \equiv E \left[W_t \left(Y \left(a_1, M_1^*(a_2), M_2^*(a_3, a_4), \dots, M_K^*(a_{(2^{K-1}+1, 2^K)}) \right) \right) \right]$$

28 where $W_t(\cdot)$ is a transfer function.

29 Typically, we consider the identity function as the transfer function ($W_t(x) = x$)

30 in the case of studying time-independent outcome, and thus, the multi-mediation

31 parameter in *Definition 3* is simplified as the expectation of the counterfactual outcome

32 suppose that $(A, M_{(1,K)})$ is set to $(a_1, M_1^*(a_2), M_2^*(a_3, a_4), \dots, M_K^*(a_{(2^{K-1}+1, 2^K)}))$.

33 Additionally, for survival outcome, the transfer function is specified as an indicator

34 function with respect to the time variable t ($W_t(x) = I(x \geq t)$), and subsequently, the

1 $\vartheta_K(a_{(1,2^K)}|W_t)$ can be rewritten as the survival function of the counterfactual outcome.
 2 Based on *Definitions 2* and *3*, we can use ϑ to quantitatively define PSE.

3 *Definition 4.* (Quantitative definition of PSE)

$$4 \quad PSE_K(d, a_{(1:2^K, -d)}, a_{(1)}^*, a_{(0)}^* | Q, W_t)$$

$$5 \quad \equiv Q(\vartheta_K([a_{(1:d-1)}, a_{(1)}^*, a_{(d+1:2^K)}]|W_t), \vartheta_K([a_{(1:d-1)}, a_{(0)}^*, a_{(d+1:2^K)}]|W_t)),$$

6 where $Q(\cdot)$ is a nonspecific comparative function.

7 In *Definition 4*, $PSE_K(d, a_{(1:2^K, -d)}, a_{(1)}^*, a_{(0)}^* | Q, W_t)$ is defined in terms of the
 8 change of ϑ_K by changing the value of a_d from $a_{(0)}^*$ to $a_{(1)}^*$ when all other
 9 variables are fixed as $a_{(1:2^K, -d)}$, and the definition of multi-mediation parameters
 10 guarantees that the influence of changing a_d reflects the effect of the exposure on the
 11 outcome through the d -th path. The interpretation of $PSE_K(d, a_{(1:2^K, -d)}, a_{(1)}^*, a_{(0)}^* | Q, W_t)$
 12 is determined by $Q(x_1, x_2)$. For example, if Y is a binary variable and $W_t(x) = x$,
 13 three types of $Q(x_1, x_2)$ are commonly used in medical research:

14 (1) $Q(x_1, x_2) = (x_1 - x_2)$ for the risk difference scale,

15 (2) $Q(x_1, x_2) = x_1/x_2$ for the risk ratio scale, and

16 (3) $Q(x_1, x_2) = \frac{x_1}{(1-x_1)} / \frac{x_2}{(1-x_2)}$ for the odds ratio scale.

17 Furthermore, when Y is the survival time and $W_t(x) = I(x \geq t)$, the causal effect of
 18 interest is usually defined on the hazard function, and the corresponding comparative
 19 functions are formulated as

20 (4) $Q(x_1(t), x_2(t)) = \frac{\frac{dx_1(t)}{dt}}{x_1(t)} / \frac{\frac{dx_2(t)}{dt}}{x_2(t)} = \lambda_1(t)/\lambda_2(t)$ for the hazard ratio scale, and

21 (5) $Q(x_1(t), x_2(t)) = \frac{\frac{dx_1(t)}{dt}}{x_1(t)} - \frac{\frac{dx_2(t)}{dt}}{x_2(t)} = \lambda_1(t) - \lambda_2(t)$ for the hazard difference scale,

22 in which $x_1(t)$ and $x_2(t)$ are two survival functions, and $\lambda_1(t)$ and $\lambda_2(t)$ are the
 23 corresponding hazard functions. For simplicity, we use $Q(x_1, x_2) = (x_1 - x_2)$
 24 throughout Section 2.

25 Although $a_{(1:2^K, -d)}$ can take any values in *Definition 4*, Denial et al. concluded
 26 that there are only $(2^K)!$ ways of decomposing the total effect into PSEs (Daniel, *et*
 27 *al.*, 2015). Following previous works (Lin and VanderWeele, 2017; Wang, *et al.*, 2013),
 28 we use one of the ways to specify PSE, and the expression is shown as follows:

29 *Definition 5.* (PSE for decomposition of TE).

$$30 \quad PSE_K(d, a_{(1)}^*, a_{(0)}^* | W_t) \equiv \vartheta_K([\bar{a}_{(1)}^*_d, \bar{a}_{(0)}^*_{2^K-d}] | W_t) - \vartheta_K([\bar{a}_{(1)}^*_{d-1}, \bar{a}_{(0)}^*_{2^K-d+1}] | W_t)$$

$$31 \quad TE_K(a_{(1)}^*, a_{(0)}^* | W_t) \equiv \sum_{d=1}^{2^K} PSE_K(d, a_{(1)}^*, a_{(0)}^* | W_t)$$

32 where $\bar{a}_{(1)}^*_i$ and $\bar{a}_{(0)}^*_i$ represents a vector composed by $a_{(1)}^*$ and $a_{(0)}^*$ with length i ,
 33 respectively. Here $TE_K(a_{(1)}^*, a_{(0)}^* | W_t)$ is equal to $E[W_t(Y(a_{(1)}^*))] - E[W_t(Y(a_{(0)}^*))]$ by
 34 consistency, which is the traditional counterfactual definition of the causal effect of A
 35 on Y with two levels $a_{(1)}^*$ and $a_{(0)}^*$.

1 Two issues merit to be noticed. First, if there is one mediator (i.e. $K=1$), $PSE_2(1)$
2 and $PSE_2(2)$ are exactly the same as natural direct effect and indirect effect,
3 respectively, defined by Robins and Greenland (Robins and Greenland, 1992). Second,
4 it is the same as the concept of PSE proposed by Avin (Avin, *et al.*, 2005), but we here
5 propose a notation and framework which is suitable for the cases with any arbitrary
6 number of ordered multiple mediators. However, as noted by Avin et al.,
7 $\vartheta_K(a_{(1,2^K)}|W_t)$ as well as most PSEs are not identifiable under conventional
8 assumptions (Avin, *et al.*, 2005; Vanderweele, *et al.*, 2014). Two approaches are
9 available to address this issue. First, we can use the interventional approach adopting
10 an alternative definition instead of traditional PSE for effect decomposition. This
11 definition has been widely used in natural direct and indirect effects with time-varying
12 confounders (Lin, *et al.*, 2017; VanderWeele and Tchetgen Tchetgen, 2017;
13 VanderWeele and Vansteelandt, 2014), and have been extended to the settings with
14 ordered multiple mediators (Lin and VanderWeele, 2017). We will review this approach
15 in Section 2.2. The second approach is to partially decompose the total effect into $K+1$
16 paths, instead completely decompose the total effect into 2^K PSE. This method is
17 commonly adapted by researchers for two or three mediators. We will propose a general
18 form for any arbitrary number of mediators in Section 2.3.

19 2.2. Approach 1: interventional approach based on randomized interven-
20 tional analogue of path-specific effect (iPSE)

21 Before defining the iPSE, we must define “conditional iterative random draw of
22 counterfactual mediators” and a “interventional multi-mediation parameter” in advance,
23 as *Definition 2.a* and *Definition 3.a*.

24 *Definition 2.a.* (Conditional iterative random draw of counterfactual mediators, $G_k(a_{(1,2^{k-1})})$)
25 All definitions are conditional on baseline confounders C_0 . $G_1(a_1)$ is a random draw of
26 $M_1(a_1)$. $G_2(a_1, a_2)$ is a random draw of $M_2(a_1, G_1(a_2))$, which is the counterfactual
27 value of M_2 suppose (A, M_1) is set to $(a_1, G_1(a_2))$. Consequently, for $k \in \{3, \dots, K\}$,
28 let $G_k(a_{(1,2^{k-1})})$ be a random draw of $M_k(a_1, G_1(a_2), \dots, G_{k-1}(a_{(2^{k-2}+1, 2^{k-1})}))$, which is
29 the counterfactual value of M_k suppose $(A, M_{(1,k-1)})$ is set to
30 $(a_1, G_1(a_2), \dots, G_{k-1}(a_{(2^{k-2}+1, 2^{k-1})}))$. For any $k \in \{1, \dots, K\}$, G_k is a function of $a_{(1,2^{k-1})}$.

31 On the basis of *Definition 2.a*, we can further define multi-mediation parameters in an
32 interventional form as *Definition 3.a*.

33 *Definition 3.a.* (Interventional multi-mediation parameter $\varphi_K(a_{(1,2^K)}|W_t)$)
34
$$\varphi_K(a_{(1,2^K)}|W_t) \equiv E[W_t(Y(a_1, G_1(a_2), G_2(a_3, a_4), \dots, G_K(a_{(2^{K-1}+1, 2^K)}))))]$$

35 Similar to *Definition 3*, the transfer function can be specified as the identity function

1 for the time-independent outcome or the indicator function with respect to time t for
 2 survival outcome. As the result, the interventional multi-mediation parameter in
 3 *Definition 3.a* is the expectation of a transferred counterfactual outcome suppose that
 4 $(A, M_{(1,K)})$ is set to $(a_1, G_1(a_2), G_2(a_3, a_4), \dots, G_K(a_{(2^{K-1}+1, 2^K)}))$. Next, we can use
 5 φ to define iPSE.

6 *Definition 4.a.* (Randomized interventional analogue of path-specific effect (iPSE))

$$7 \quad iPSE(d, a_{(1:2^K; -d)}, a_{(1)}^*, a_{(0)}^* | Q, W_t)$$

$$8 \quad \equiv Q(\varphi_K([a_{(1:d-1)}, a_{(1)}^*, a_{(d+1:2^K)}] | W_t), \varphi_K([a_{(1:d-1)}, a_{(0)}^*, a_{(d+1:2^K)}] | W_t)),$$

9 $iPSE(d, a_{(1:2^K; -d)}, a_{(1)}^*, a_{(0)}^* | Q, W_t)$ is defined in terms of the change of φ_K by
 10 changing the value of a_d from $a_{(0)}^*$ to $a_{(1)}^*$ when all other variables are fixed as
 11 $a_{(-d)}$. Similar to Definition 5, we specify iPSE using the following expression for
 12 convenience of decomposition and define the randomized interventional analogue of
 13 total effect (iTE):

14 *Definition 5.a.* (iPSE for decomposition of iTE).

$$15 \quad iPSE_K(d, a_{(1)}^*, a_{(0)}^* | W_t) \equiv \varphi_K([\bar{a}_{(1)d}^*, \bar{a}_{(0)2^K-d}^*] | W_t) - \varphi_K([\bar{a}_{(1)d-1}^*, \bar{a}_{(0)2^K-d+1}^*] | W_t)$$

$$16 \quad iTE_K(a_{(1)}^*, a_{(0)}^* | W_t) \equiv \sum_{d=1}^{2^K} iPSE_K(d, a_{(1)}^*, a_{(0)}^* | W_t)$$

17 2.3. Approach 2: Partial decomposition approach

18 Although the interventional approach can provide completely decomposition with
 19 2^K paths, three limitations merit to be noticed. First, the definition of iPSE, although
 20 obtains the essence of PSE, still deviates from the traditional definition. Second, the
 21 sum of iPSE is also the analogue of total effect (iTE), instead a real one. Third, the
 22 interpretation of the definition based on iterative random draw is complicated.
 23 Therefore, some researchers prefer to keep the original definition of PSE. As a trade-
 24 off, the effect can only be partially decomposed into $K+1$ paths, instead of 2^K . The
 25 effects corresponding to these paths are termed partPSEs through this article and are
 26 exactly the sum of several non-identified PSEs. In previous literature, this partial
 27 decomposition has been applied to two or three mediators (Cho and Huang, 2019;
 28 Huang and Yang, 2017; Huang and Cai, 2015). An interventional analogue has been
 29 proposed (Moreno-Betancur and Carlin, 2018; Vansteelandt and Daniel, 2017). In this
 30 study, we propose a general definition for partial PSEs. We will identify the partial PSEs
 31 and discuss the assumption required for identification in Section 2.4. Similarly, we first
 32 define “Nested iterative counterfactual mediators” and a “partial multi-mediation
 33 parameter” as *Definition 2.b* and *Definition 3.b*, for simplifying the notation.

34 *Definition 2.b.* (Nested iterative counterfactual mediators, $M_k^\dagger(e_{(1,k)})$).

1 $M_1^\dagger(e_1) \equiv M_1(e_1)$. For $k \in \{2, \dots, K\}$, let $M_k^\dagger(e_{(1,k)}) \equiv M_k(e_k, M_1^\dagger(e_1), \dots, M_{k-1}^\dagger(e_{(1,k-1)}))$,
2 which is the counterfactual value of M_k suppose $(A, M_{(1,k-1)})$ is set to
3 $(e_k, M_1^\dagger(e_1), \dots, M_{k-1}^\dagger(e_{(1,k-1)}))$. For any $k \in \{1, \dots, K\}$, M_k^\dagger is a function of $e_{(1,k)}$.

4 On the basis of *Definition 2.b*, we can further define partial multi-mediation parameter
5 in a general form as *Definition 3.b*.

6 *Definition 3.b.* (Partial multi-mediation parameter $\psi_K(a_1, e_{(1,K)}|W_t)$)
7 $\psi_K(a_1, e_{(1,K)}|W_t) \equiv E \left[W_t \left(Y \left(a_1, M_1^\dagger(e_1), M_2^\dagger(e_{(1,2)}), M_3^\dagger(e_{(1,3)}), \dots, M_K^\dagger(e_{(1,K)}) \right) \right) \right]$
8 where W_t is a transfer function.

9 *Definition 3.b* implies that the partial multi-mediation parameter represents the
10 cumulative effect of multiple paths, while the interventional multi-mediation parameter
11 in *Definition 3.a* can be used to quantify each path. In Section 3, we provide a theorem
12 to detail the relationship between partial PSE and interventional PSE in terms of
13 survival analysis when analytical estimators are available. We next use the partial multi-
14 mediation parameter in *Definition 3.b* to define the partPSE.

15 *Definition 4.b.* (Partial path-specific effect (partPSE))
16 $partPSE_K(0, e_{(1,K)}, a_{(1)}^*, a_{(0)}^*|Q, W_t) \equiv Q \left(\psi_K(a_{(1)}^*, e_{(1,K)}|W_t) - \psi_K(a_{(0)}^*, e_{(1,K)}|W_t) \right)$
17 $partPSE_K(g, e_{(1,K;-g)}, a_{(1)}^*, a_{(0)}^*|Q, W_t)$
18 $\equiv Q \left(\psi_K(a_1, [e_{(1,g-1)}, a_{(1)}^*, e_{(g+1,K)}]|W_t) - \psi_K(a_1, [e_{(1,g-1)}, a_{(0)}^*, e_{(g+1,K)}]|W_t) \right)$
19 for $g \in \{1, \dots, K\}$, where $Q(\cdot)$ a nonspecific comparative function.

20 In *Definition 4.b*, $partPSE(g, e_{(1,K;-g)}, a_{(1)}^*, a_{(0)}^*|Q, W_t)$ is defined in terms of
21 the change of ψ_K by changing the value of e_g from $a_{(0)}^*$ to $a_{(1)}^*$ when all other
22 variables are fixed as $e_{(1,K;-g)}$, and the definition of multi-mediation parameters
23 guarantees that the influence of changing e_g reflects the effect of the exposure on the
24 outcome through M_g , which includes all path passing or not the following mediators
25 ($M_{(g+1,K)}$), but not through the previous mediators (i.e. $M_{(1,g-1)}$). Similarly, we further
26 specify the value of $(a_1, e_{(1,K)})$ for all partPSEs in order to ensure that the sum is equal
27 to TE as follows:

28 *Definition 5.b.* (partPSE for decomposition of TE).
29 $partPSE_K(0, a_{(1)}^*, a_{(0)}^*|W_t) \equiv \psi_K \left([a_{(1)}^*, \bar{a}_{(0)K}^*] |W_t \right) - \psi_K \left([a_{(0)}^*, \bar{a}_{(0)K}^*] |W_t \right)$
30 $partPSE_K(g, a_{(1)}^*, a_{(0)}^*|W_t)$
31 $\equiv \psi_K \left(a_{(1)}^*, [\bar{a}_{(1)g}^*, \bar{a}_{(0)K-g}^*] |W_t \right) - \psi_K \left(a_{(1)}^*, [\bar{a}_{(1)g-1}^*, \bar{a}_{(0)K-g+1}^*] |W_t \right)$
32 for $g > 0$, As a result, the sum of all partPSE will equal to total effect, i.e.
33 $\sum_{g=0}^K partPSE_K(g, a_{(1)}^*, a_{(0)}^*|W_t) = TE$ by consistency.

1 2.4. Identification

2 In this section, we discuss the identification process and the required assumption
3 for iPSE and partPSE. For PSE, four assumptions are required:

4 *Assumption 1.* Unconfoundedness among exposure and outcome.

5
$$Y(a, m_{(1,K)}) \perp\!\!\!\perp A | C_0$$

6 *Assumption 2.* Unconfoundedness among mediators and outcome.

7
$$Y(a, m_{(1,K)}) \perp\!\!\!\perp M_k | C_{(0,k)}, A, M_{(1,k-1)} \text{ for } k \in \{1, 2, \dots, K\}$$

8 *Assumption 3.* Unconfoundedness among exposure and mediators.

9
$$M_k(a, m_{(1,k-1)}) \perp\!\!\!\perp A | C_0 \text{ for } k \in \{1, 2, \dots, K\}$$

10 *Assumption 4.* Unconfoundedness among mediators.

11
$$M_k(a, m_{(1,k-1)}) \perp\!\!\!\perp M_k | C_{(0,j)}, A, M_{(1,j-1)} \text{ for } j \in \{1, 2, \dots, k-1\} \text{ and } k \in \{2, \dots, K\}$$

12 Under consistency assumption and *Assumptions 1* to *4*, interventional multi-
13 mediation parameter can be identified as

14
$$\begin{aligned} & \varphi_K(a_{(1,2^K)} | W_t) \\ 15 &= \int_{c_0} \int_{m_{(1,K)}} E[W_t(Y(a_1, m_{(1,K)})) | c_0] \prod_{k=1}^K dF_{G_k(a_{(2^{k-1}+1, 2^k)} | c_0)}(m_k | c_0) dF_{C_0}(c_0) \\ 16 &= \int_{c_0} \int_{m_{(1,K)}} \Gamma(c_0, a_1, m_{(1,K)} | W_t) \prod_{k=1}^K H_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0) dF_{C_0}(c_0). \end{aligned} \quad (1)$$

17 where $\Gamma(c_0, a_1, m_{(1,K)} | W_t) =$

18
$$\int_{c_{(1,K)}} E[W_t(Y) | a_1, c_{(0,K)}, m_{(1,K)}] \prod_{k=1}^K dF_{C_k | C_{(0,k-1)}, A, M_{(1,k-1)}}(c_k | c_{(0,k-1)}, a_1, m_{(1,k-1)})$$

19 and $H_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0) =$

20
$$\int_{m_{(1,k-1)}} \int_{c_{(1,k)}} dF_{M_k | A, M_{(1,k-1)}, C_{(0,k)}}(m_k | a_{2^{k-1}+1}, m_{(1,k-1)}, c_{(0,k)}) \times$$

21
$$\prod_{j=1}^k dF_{C_j | A, M_{(1,j-1)}, C_{(0,j-1)}}(c_j | a_{2^{k-1}+1}, m_{(1,j-1)}, c_{(0,j-1)}) \times$$

22
$$\prod_{j=1}^{k-1} H_j(m_j, a_{(2^{k-1}+2^{j-1}+1, 2^{k-1}+2^j)}, c_0)$$

23 The details about the identification process and *Assumptions 1* to *4* have been described
24 in previous literature (Lin and VanderWeele, 2017).

25 Compared with iPSE, partPSE required two extra assumptions for identification:

26 *Assumption 5.* Confounders among mediators and outcome is not affected by previous
27 covariates.

28
$$Y(a, m_{(1,K)}) \perp\!\!\!\perp (M_1(e_1), M_2(e_2, m_1), \dots, M_K(e_K, m_{(1,K-1)})) | C_0$$

29 *Assumption 6.* Confounders among mediators is not affected by previous covariates.

30
$$M_k(e_k, m_{(1,k-1)}) \perp\!\!\!\perp (M_1(e_1), M_2(e_2, m_1), \dots, M_{k-1}(e_{k-1}, m_{(1,k-2)})) | C_0 \text{ for } k \in \{2, \dots, K\}$$

31

32 Since the presence of time-varying confounders $C_{(1,k)}$ conflicts with *Assumptions 5*
33 and *6*, an assumption of no time-varying confounders is further required for the
34 identification of partPSE. Details about *Assumptions 5* and *6* will be illustrated in
35 Appendix Sections 1.1 and 1.2.

36 Under consistency assumption and *Assumptions 1* to *6*, partial multi-mediation

1 parameter $\psi_K(a_1, e_{(1,K)}|W_t)$ is identified as
2 $\psi_K(a_1, e_{(1,K)}|W_t)$
3 $= \int_{c_0, m_{(1,K)}} E \left[W_t \left(Y(a_1, m_{(1,K)}) \right) | C_0 = c_0 \right] \prod_{k=1}^K dF_{M_k(e_k, m_{(1,k-1)})|c_0}(m_k|c_0) dF_{C_0}(c_0)$
4 $= \int_{c_0, m_{(1,K)}} E \left[W_t(Y) | a_1, c_0, m_{(1,K)} \right] \prod_{k=1}^K dF_{M_k|c_0, A, M_{(1,k-1)}}(m_k|c_0, e_k, m_{(1,k-1)}) dF_{C_0}(c_0)$ (2)

5 The identification of (2) is shown in Appendix Section 1.3. If we assume previous
6 mediator will not affect the following mediator, the partial multi-mediation parameter
7 can be rewritten as

8 $\psi_K(a_1, e_{(1,K)}|W_t)$
9 $= \int_{c_0, m_{(1,K)}} E \left[W_t \left(Y(a_1, m_{(1,K)}) \right) | C_0 = c_0 \right] \prod_{k=1}^K dF_{M_k(e_k)|c_0}(m_k|c_0) dF_{C_0}(c_0)$
10 $= \int_{c_0, m_{(1,K)}} E \left[W_t(Y) | a_1, c_0, m_{(1,K)} \right] \prod_{k=1}^K dF_{M_k|c_0, A}(m_k|c_0, e_k) dF_{C_0}(c_0)$ (3)

11 Formula (3) is exactly the multi-mediation parameter under paralleled mediators used
12 by previous literatures (Taguri, *et al.*, 2015; Wang, *et al.*, 2013). Therefore, we conclude
13 that the paralleled multi-mediation parameter is a special case of the partial multi-
14 mediation parameter. Two multi-mediation parameters (2) and (3) are decomposing a
15 total causal effect into $K+1$ pathways.

16 *Assumptions 5 and 6* hinge the time-varying confounders even if all these
17 confounders are collected. It is likely to be violated if the time period of all multiple
18 mediators is long. In addition, as mentioned previously, partPSE cannot completely
19 decompose the effect into 2^K paths. That is the trade-off to keep traditional definition.
20 In cases of one mediator, the interventional analogue of natural direct and indirect
21 effects will reduce to its standard definition when mediator-outcome confounders are
22 not affected by exposure (Vanderweele, *et al.*, 2014), even under time-varying settings
23 (VanderWeele and Tchetgen Tchetgen, 2017). By contrast, for multiple mediators
24 without model assumptions, iPSE is not a general form of partPSE, even if time-varying
25 confounders are absent. Given parametric models for outcome and mediators, the
26 partPSE can be decomposed into several iPSEs, and the detail is shown in Section 3.

27 2.5. Definition of PSE for survival outcome

28 In Section 2.5 and what follows, we focus on the context when survival time is the
29 outcome of interest (i.e $Y \equiv T$). We applied *Approaches 1 and 2* to define PSE for
30 survival outcome, separately. Before deriving PSE, the multi-mediation parameters in
31 *Definition 3.a* and *Definition 3.b* are reformed as the survival functions of the
32 counterfactual outcome. More specifically, given $W_t(x) = I(x \geq t)$, equations (1) and
33 (2) can be rewritten as

34 $\varphi_K^S(a_{(1,2^K)}; t) \equiv \varphi_K(a_{(1,2^K)}|W_t = I(x \geq t))$
35 $= \int_{c_0} \int_{m_{(1,K)}} \Gamma^S(c_0, a_1, m_{(1,K)}; t) \prod_{k=1}^K H_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0) dF_{C_0}(c_0)$, (4)

36 where

37 $\Gamma^S(c_0, a_1, m_{(1,K)}; t) \equiv \Gamma(c_0, a_1, m_{(1,K)}|W_t = I(x \geq t))$

$$1 \quad = \int_{c_{(1,K)}} S_Y(t|a_1, c_{(0,K)}, m_{(1,K)}) \prod_{k=1}^K dF_{C_k|C_{(0,k-1)}, A, M_{(1,k-1)}}(c_k|c_{(0,k-1)}, a_1, m_{(1,k-1)})$$

2 and

$$3 \quad \psi_K^S(a_1, e_{(1,K)}; t) \equiv \psi_K(a_1, e_{(1,K)}|W_t = I(x \geq t))$$

$$4 \quad = \int_{c_0, m_{(1,K)}} S_Y(t|a_1, c_0, m_{(1,K)}) \prod_{k=1}^K dF_{M_k|C_0, A, M_{(1,k-1)}}(m_k|c_0, e_k, m_{(1,k-1)}) dF_{C_0}(c_0)$$

5 (5)

6 $S_Y(t)$ is the survival function with respect to survival outcome Y , and
7 $\psi_K^S(a_1, e_{(1,K)}; t)$ and $\varphi_K^S(a_{(1,2^K)}; t)$ are exactly the survival function of the
8 counterfactual outcome by the definition. Let $\lambda_Y(t)$ is the hazard function of Y . We
9 can define the corresponding hazard functions of the counterfactual outcome as

$$10 \quad \tilde{\lambda}_\varphi(a_{(1,2^K)}; t) \equiv \lambda_{Y(a_1, G_1(a_2), G_2(a_3, a_4), \dots, G_K(a_{2^{K-1}+1, 2^K}))}(t) \equiv -\frac{d\varphi_K^S(a_{(1,2^K)}; t)/dt}{\varphi_K^S(a_{(1,2^K)}; t)}, \text{ and}$$

$$11 \quad \tilde{\lambda}_\psi(a_1, e_{(1,K)}; t) \equiv \lambda_{Y(a_1, M_1^\dagger(e_{1,1}), M_2^\dagger(e_{1,2}), \dots, M_K^\dagger(e_{1,K}))}(t) \equiv -\frac{d\varphi_K^S(a_{(1,2^K)}; t)/dt}{\varphi_K^S(a_{(1,2^K)}; t)}.$$

12 (6)

13 Since the counterfactual survival function are identified above, we can subsequently
14 obtain the identified hazard functions in (6) by plugging the formulas of (4) and (5).
15 Based on hazard functions, iPSE and partPSE in the hazard difference (HD) scale,
16 termed $iPSE_K^{HD}$ and $partPSE_K^{HD}$, are defined as follows:

$$17 \quad iPSE_K^{HD}(d, a_{(1)}^*, a_{(0)}^*)$$

$$18 \quad = \tilde{\lambda}_\varphi(a_{(1,2^K)} = (\bar{a}_{(1)d}^*, \bar{a}_{(0)2^K-d}^*); t) - \tilde{\lambda}_\varphi(a_{(1,2^K)} = (\bar{a}_{(1)d-1}^*, \bar{a}_{(0)2^K-d+1}^*); t)$$

19 for $d \in \{1, \dots, 2^K\}$, and

$$20 \quad partPSE_K^{HD}(g, a_{(1)}^*, a_{(0)}^*)$$

$$21 \quad = I_{(g=0)}[\tilde{\lambda}_\psi(a_1 = a_{(1)}^*, e_{(1,K)}; t) - \tilde{\lambda}_\psi(a_1 = a_{(0)}^*, e_{(1,K)}; t)] +$$

$$22 \quad I_{(g>0)}[\tilde{\lambda}_\psi(a_1, e_{(1,K)} = (\bar{a}_{(1)g}^*, \bar{a}_{(0)K-g}^*); t) - \tilde{\lambda}_\psi(a_1, e_{(1,K)} = (\bar{a}_{(1)g-1}^*, \bar{a}_{(0)K-g+1}^*); t)]$$

23 for $g \in \{0, \dots, K\}$

24 (7)

25 where $I_{(g=0)}$ and $I_{(g>0)}$ are indicator functions for $g = 0$ and $g > 0$, respectively.
26 Similarly, for the log transformed hazard ratio (HR) scale, iPSE and partPSE can be
27 defined as follows:

$$28 \quad iPSE_K^{HR}(d, a_{(1)}^*, a_{(0)}^*)$$

$$29 \quad = \log(\tilde{\lambda}_\varphi(a_{(1,2^K)} = (\bar{a}_{(1)d}^*, \bar{a}_{(0)2^K-d}^*); t)) - \log(\tilde{\lambda}_\varphi(a_{(1,2^K)} = (\bar{a}_{(1)d-1}^*, \bar{a}_{(0)2^K-d+1}^*); t))$$

30 for $d \in \{1, \dots, 2^K\}$ and,

$$31 \quad partPSE_K^{HR}(g, a_{(1)}^*, a_{(0)}^*)$$

$$32 \quad = I_{(g=0)}[\log(\tilde{\lambda}_\psi(a_1 = a_{(1)}^*, e_{(1,K)}; t)) - \log(\tilde{\lambda}_\psi(a_1 = a_{(0)}^*, e_{(1,K)}; t))] +$$

$$33 \quad I_{(g>0)}[\log(\tilde{\lambda}_\psi(a_1, e_{(1,K)} = (\bar{a}_{(1)g}^*, \bar{a}_{(0)K-g}^*); t))$$

$$34 \quad - \log(\tilde{\lambda}_\psi(a_1, e_{(1,K)} = (\bar{a}_{(1)g-1}^*, \bar{a}_{(0)K-g+1}^*); t))]$$

35 for $g \in \{0, \dots, K\}$.

36 (8)

1 **3. Estimation for PSE with survival outcome**

2 In this section, we applied Aalen's additive hazards model to derive PSE in HD
 3 scale and Cox's proportional hazards model in log HR scale. We propose a parametric
 4 approach in which the statistical models of survival outcome, mediators and
 5 confounders are specified. We mainly focus on the case of assuming mediators'
 6 distribution are Gaussian in order to derive the analytic form.

7 3.1 Model specification for mediators and confounders

8 For the k -th mediators and confounders, the regression models are described as
 9 follows:

$$10 \quad M_k = \alpha_k^M C_0 + \beta_k^M A + \sum_{h=1}^k \gamma_{kh}^M C_h + I_{(k>1)} \left[\sum_{h=1}^{k-1} \delta_{kh}^M M_h \right] + \varepsilon_{M,k}$$

$$11 \quad C_k = \alpha_k^C C_0 + \beta_k^C A + I_{(k>1)} \left[\sum_{h=1}^{k-1} \gamma_{kh}^C C_h + \sum_{h=1}^{k-1} \delta_{kh}^C M_h \right] + \varepsilon_{C,k} \quad (9)$$

12 The error terms $\{\varepsilon_{M,k}\}$ and $\{\varepsilon_{C,k}\}$ are independent and normally distributed with
 13 mean zero and respective variances, $\{\sigma_{M,k}^2\}$ and $\{\sigma_{C,k}^2\}$. The parameters above

$$14 \quad \boldsymbol{\theta} \equiv \{\boldsymbol{\alpha} = \{\alpha_k^M, \alpha_k^C | k = 1, \dots, K\}, \boldsymbol{\beta} = \{\beta_k^M, \beta_k^C | k = 1, \dots, K\}, \boldsymbol{\sigma}^2 = \{\sigma_{M,k}^2, \sigma_{C,k}^2 | k = 1, \dots, K\},$$

$$15 \quad \boldsymbol{\gamma} = \{\gamma_{11}^M, \{\gamma_{kh}^M, \gamma_{kk}^M, \gamma_{kh}^C | k = 2, \dots, K; h = 1, \dots, (k-1)\}\},$$

$$16 \quad \boldsymbol{\delta} = \{\delta_{kh}^M, \delta_{kh}^C | k = 2, \dots, K; h = 1, \dots, (k-1)\}$$

17 can be estimated using the maximum likelihood approach, and the maximum likelihood
 18 estimator (MLE) of $\boldsymbol{\theta}$ is denoted as $\hat{\boldsymbol{\theta}}$. Since the partial decomposition approach
 19 requires the assumption of no-confounders affected by previous covariates, the
 20 regression models of mediators are modified to drop out the time-varying confounders
 21 ($C_{(1:K)}$) from mean when we study partial decomposition. The models of mediators are
 22 modified as follows:

$$23 \quad M_k = \alpha_k^M C_0 + \beta_k^M A + I_{(k>1)} \left[\sum_{h=1}^{k-1} \delta_{kh}^M M_h \right] + \varepsilon_{M,k} \text{ for } k = 2, \dots, K \quad (10)$$

24 To obtain the analytic forms of (4)-(8), we applied moment generating function
 25 uniqueness theorem to characterize $H_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0)$ by *Theorem 1*.

26 *Theorem 1.* Let $H_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0) = h_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0) dm_k$. If media-
 27 tors and confounders follow the regression models as above, then
 28 $h_k(m_k, a_{(2^{k-1}+1, 2^k)}, c_0)$ is a Gaussian probability density function with mean
 29 $\mu_k^M(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^k)}, c_0)$ and variance $\tau_k^{2M}(\boldsymbol{\theta})$. Moreover, $\mu_k^M(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^k)}, c_0)$ and
 30 $\tau_k^{2M}(\boldsymbol{\theta})$ have recursive forms as follows:

$$31 \quad \mu_k^M(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^k)}, c_0) = \alpha_k^M c_0 + \beta_k^M a_{2^{k-1}+1} + \sum_{h=1}^k \gamma_{kh}^M \times$$

$$32 \quad \mu_h^C(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^{k-1}+2^{h-1})}, c_0) + I_{(k>1)} \left[\sum_{h=1}^{k-1} \delta_{kh}^M \times \mu_h^M(\boldsymbol{\theta}, a_{(2^{k-1}+2^{h-1}+1, 2^{k-1}+2^h)}, c_0) \right]$$

33 for $k = 1, \dots, K$, where

$$\begin{aligned}
& \mu_h^C(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^{k-1}+2^{h-1})}, c_0) = \alpha_h^C c_0 + \beta_h^C a_{2^{k-1}+1} + I_{(k>1)} [\sum_{h'=1}^{h-1} \gamma_{hh'}^C \\
& \quad \times \mu_{h'}^C(\boldsymbol{\theta}, a_{(2^{k-1}+1, 2^{k-1}+2^{h'-1})}, c_0) + \sum_{h'=1}^{h-1} \delta_{hh'}^C \times \mu_{h'}^M(\boldsymbol{\theta}, a_{(2^{k-1}+2^{h'-1}+1, 2^{k-1}+2^{h'})}, c_0)] \\
& \text{and } \tau_k^M(\boldsymbol{\theta}) = \sigma_{M,k}^2 + \sum_{h=1}^k (\sum_{s=h}^k \gamma_{ks}^M \times (E_{ksh}))^2 \sigma_{C,h}^2 + \\
& \quad I_{(k>1)} [\sum_{h=1}^{k-1} (\delta_{kh}^M + \sum_{s=h+1}^k \gamma_{ks}^M \times (F_{ksh}))^2 \tau_h^M(\boldsymbol{\theta})], \text{ in which} \\
& E_{ksh} = I_{(s>h)} [\sum_{l=1}^{s-1} E_{klh} \times \gamma_{sl}^C] + 1_{(s=h)} \text{ and } F_{ksh} = I_{(s>h)} [\delta_{s1}^C + \sum_{l=1}^{s-1} F_{klh} \times \gamma_{sl}^C].
\end{aligned}$$

The proof detail is presented in Appendix Section 2.1. Based on *Theorem 1*, we next derive the closed forms of estimators for iPSE and partPSE under HD scale using Aalen's additive hazards model in Section 3.2 and under log HR scales using Cox's proportional hazards model in Section 3.3.

3.2 Aalen's additive hazards model

Following the regression setting of mediators and confounders, we apply Aalen's additive hazards model for the outcome Y as follows:

$$\lambda_Y(t|A, C_{(0,K)}, M_{(1,K)}) = \lambda_0(t) + \alpha^Y C_0 + \beta^Y A + \sum_{h=1}^K \gamma_h^Y C_h + \sum_{h=1}^K \delta_h^Y M_h, \quad (11)$$

where $\lambda_0(t)$ is the baseline hazard and $\boldsymbol{\theta}_y^{\text{Aalen}} = (\alpha^Y, \beta^Y, \boldsymbol{\gamma}_h^Y = \{\gamma_h^Y | h = 1, \dots, K\}, \boldsymbol{\delta}_h^Y = \{\delta_h^Y | h = 1, \dots, K\})$ is the regression coefficient. Typically, the estimator of $\boldsymbol{\theta}_y^{\text{Aalen}}$ can be derived by the semiparametric estimating equation (Lin and Ying, 1994), and we denote the estimator as $\hat{\boldsymbol{\theta}}_y^{\text{Aalen}}$. Here, we separately introduce the estimators for iPSE_K^{HD} and partPSE_K^{HD}.

iPSE_K^{HD}

According to models (6), (9), and (11), we have the hazard function of counterfactual outcome incorporated with Aalen's additive hazards model as follows:

$$\begin{aligned}
& \tilde{\lambda}_\varphi(a_{(1,2^K)}; t) \\
& = \lambda_0(t) + (\beta^Y + (\sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \beta_j^C)) a_1 + (\alpha^Y + \sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \alpha_j^C) E(C_0) + \\
& \quad \sum_{j=1}^K Z_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \mu_j^M(\boldsymbol{\theta}, a_{(2^{j-1}+1, 2^j)}, c_0 = E(C_0)) - \sum_{j=1}^K R_j^2(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \sigma_{C,j}^2 t - \\
& \quad \sum_{j=1}^K Z_j^2(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \tau_j^M(\boldsymbol{\theta}) t
\end{aligned}$$

where

$$\begin{aligned}
& R_K(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) = \gamma_K^Y, \quad R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) = \gamma_j^Y + \sum_{d=j+1}^K R_d(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \gamma_{d,j}^C, \text{ and} \\
& Z_{K-j}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) = \delta_{K-j}^Y + I_{(k>1)} [\sum_{j^\circ=0}^{j-1} (\gamma_{(K-j^\circ)}^Y (\sum_{s=1}^{2^{(j-1)-j^\circ}} \prod_{L \in P_s(K-j^\circ, K-j)} \gamma_L^C) \delta_{(K-j^\circ)(K-j)}^C)].
\end{aligned}$$

$P_s(K-j^\circ, K-j)$ is the s^{th} subset of P , and $P = \{(a, b) | a, b \in \{K-j^\circ, K-j^\circ+1, \dots, K-j+1\} \text{ and } a > b\} \cup \Phi$, where Φ is a null set. The detailed derivation is shown in

Appendix Section 3. Consequently, iPSE_K^{HD} in (7) can be derived as

$$\text{for } d=1, \text{ iPSE}_K^{\text{HD}}(1, a_{(1)}^*, a_{(0)}^*) = (\beta^Y + \sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) \beta_j^C) (a_{(1)}^* - a_{(0)}^*), \text{ and}$$

1 for $d > 1$, $iPSE_K^{HD}(d, a_{(1)}^*, a_{(0)}^*) = \mathcal{H}\left(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}, a_{(1,2^K)} = (\bar{a}_{(1)d}^*, \bar{a}_{(0)2^K-d}^*)\right) -$
2 $\mathcal{H}\left(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}, a_{(1,2^K)} = (\bar{a}_{(1)_{d-1}}^*, \bar{a}_{(0)2^K-d+1}^*)\right)$
3 where $\mathcal{H}\left(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}, a_{(1,2^K)}\right) = \sum_{j=1}^K Z_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) \mu_j^M\left(\boldsymbol{\theta}, a_{(2^{j-1}+1, 2^j)}, c_0 = E(C_0)\right)$
4 (12)

5 In particular, when time-varying confounders (i.e. $C_{(1,K)}$) are absence, equation
6 (12) is identical to the structural equation modeling (SEM) estimator. We termed the
7 PSE without time-varying confounders as $iPSE_K^{HD}(d, a_{(1)}^*, a_{(0)}^* | C_{(1,K)} = \emptyset)$. The
8 analytic form is detailed in Appendix Section 2. For example, under two mediators, we
9 have $iPSE_2^{HD}(4, a_{(1)}^*, a_{(0)}^* | C_{(1,K)} = \emptyset) = \delta_2^Y \delta_{21}^M \beta_1^M$ which is corresponding to the
10 result of product method by the path $A \xrightarrow{\beta_1^M} M_1 \xrightarrow{\delta_{21}^M} M_2 \xrightarrow{\delta_2^Y} Y$. More examples of $iPSE_K^{HD}$
11 with and without time-varying confounder are illustrated in Appendix Section 3.

12 ***partPSE_K^{HD}***

13 Because the existence of time-varying confounders violates the assumptions of
14 partial decomposition approach, additive hazard model in (11) should be modified as

15 $\lambda_Y(t|A, C_0, M_{(1,K)}) = \lambda_0(t) + \alpha^Y C_0 + \beta^Y A + \sum_{h=1}^K \delta_h^Y M_h,$ (13)

16 Based on equations (6), (10) and (13), we derived the hazard function of counterfactual
17 outcome as below:

18 $\tilde{\lambda}_\psi(a_1, e_{(1,K)}; t)$
19 $= \lambda_0(t) + \beta^Y a_1 + \sum_{j=1}^K Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) \beta_j^M e_j + (\alpha^Y + \sum_{j=1}^K Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) \alpha_j^M) E(C_0) -$
20 $\sum_{j=1}^K \left(Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen})\right)^2 \sigma_{M,j}^2 t,$

21 where $Z_K^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) = \delta_K^Y$, $Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) = \delta_j^Y + \sum_{d=j+1}^K Z_d^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) \delta_{d,j}^M$. The detail is
22 provided in Appendix Section 3. Based on the result above, partPSE incorporating with
23 Aalen's additive hazards model in HD scale (7) is

24 $partPSE_K^{HD}(g, a_{(1)}^*, a_{(0)}^*)$
25 $= I_{(g=0)} \beta^Y (a_{(1)}^* - a_{(0)}^*) + I_{(g>0)} Z_g^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{Aalen}) \beta_g^M (a_{(1)}^* - a_{(0)}^*)$ for $g \in \{0, 1, 2, \dots, K\}$.
26 (14)

27 In 2017, Huang and Yang proposed a multi-mediator model of survival come for
28 partPSE (Huang and Yang, 2017), and they provide the corresponding estimators for
29 the case of two ordered mediators. Formula (14) is essentially an extension of Huang's
30 work to the general form of partPSE. More examples of $partPSE_K^{HD}$ are illustrated in
31 Appendix Section 3. Additionally, the partPSE in formula (14) is the sum of a certain
32 set of iPSEs under no time-varying confounder assumption. We subsequently proposed
33 *Theorem 2* to verify the relation between them.

34

1 *Theorem 2.* In the setting with K mediators and Aalen's additive hazards model, we
 2 have

$$3 \quad \text{partPSE}_K^{HD}(g, a_{(1)}^*, a_{(0)}^*) = \sum_{d \in D_g} \text{iPSE}_K^{HD}(d, a_{(1)}^*, a_{(0)}^* | C_{(1,K)} = \emptyset),$$

4 where $g \in \{1, 2, \dots, K\}$ and $D_g = \{2^{g-1} + 1 + \sum_{\{b_s\}} 2^{b_s-1} \mid \{b_s\} \subseteq \{g+1, g+2, \dots, K\}\}$.

5
 6 The proof of *Theorem 2* is presented in Appendix Section 2.2. In *Theorem 2*, D_g is a
 7 set of codes, and these codes are exactly corresponding to the paths starting from the
 8 g_{th} mediator. In another words, partPSE_K^{HD} can be further decomposed into several
 9 specific iPSE_K^{HD} which are all first mediated by the g_{th} mediator, implying that
 10 iPSE_K^{HD} contains more detailed information about mechanism than partPSE_K^{HD} for
 11 causal effect decomposition.

12 3.3 Cox's proportional hazards model

13 In this section, we further characterize iPSE_K^{HR} and partPSE_K^{HR} via Cox's
 14 proportional hazards model. Different from Aalen's additive hazards model, Cox's
 15 proportional hazards model assume that the hazard is determined by the covariates
 16 exponentially, that is

$$17 \quad \log(\lambda_Y(t|A, C_{(0,K)}, M_{(1,K)})) = \log(\lambda_0(t)) + \alpha^Y C_0 + \beta^Y A + \sum_{h=1}^K \gamma_h^Y C_h +$$

$$18 \quad \sum_{h=1}^K \delta_h^Y M_h,$$

19 (15)

20 where $\lambda_0(t)$ is the baseline hazard and $\boldsymbol{\theta}_y^{\text{cox}} = (\alpha^Y, \beta^Y, \boldsymbol{\gamma}_h^Y = \{\gamma_h^Y | h = 1, \dots, K\}, \boldsymbol{\delta}_h^Y =$
 21 $\{\delta_h^Y | h = 1, \dots, K\})$ is the corresponding parameter. Similar to Section 3.2, we derived
 22 the corresponding estimators for iPSE_K^{HR} and partPSE_K^{HR} as follows.

23 **iPSE_K^{HR}**

24 By formulas (6), (9), and (15), and the rare outcome assumption (Huang and Yang,
 25 2017) which implies $e^{-\lambda_Y(t|A, C_{(0,K)}, M_{(1,K)})} \approx 1$, one approximation of the counterfactual
 26 log hazard is

$$27 \quad \log(\tilde{\lambda}_\varphi(a_{(1,2^K)}; t)) \approx \log \lambda_0(t) + (\beta^Y + \sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \beta_j^C) a_1 +$$

$$28 \quad (\alpha^Y + \sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \alpha_j^C) E(C_0) +$$

$$29 \quad \sum_{j=1}^K Z_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \mu_j^M(\boldsymbol{\theta}, a_{(2^{j-1}+1, 2^j)}, c_0 = E(C_0)) + \sum_{j=1}^K Z_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \tau_j^{2^M}(\boldsymbol{\theta}).$$

30 where $R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y)$ and $Z_K(\boldsymbol{\theta}, \boldsymbol{\theta}_y)$ have been defined in Section 3.2. Derivation of the
 31 above expression is in Appendix Section 4. We then derived the analytic forms of (8)
 32 as follows:

33 for $d = 1$, $\text{iPSE}_K^{HR}(1, a_{(1)}^*, a_{(0)}^*) \approx (\beta^Y + (\sum_{j=1}^K R_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \beta_j^C)) (a_{(1)}^* - a_{(0)}^*)$, and

34 for $d > 1$, $\text{iPSE}_K^{HR}(d, a_{(1)}^*, a_{(0)}^*) \approx \mathcal{H}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}, a_{(1,2^K)} = (\bar{a}_{(1)}^*_{d-1}, \bar{a}_{(0)}^*_{2^K-d})) -$

$$35 \quad \mathcal{H}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}, a_{(1,2^K)} = (\bar{a}_{(1)}^*_{d-1}, \bar{a}_{(0)}^*_{2^K-d+1}))$$

36 where $\mathcal{H}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}, a_{(1,2^K)}) = \sum_{j=1}^K Z_j(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{cox}}) \mu_j^M(\boldsymbol{\theta}, a_{(2^{j-1}+1, 2^j)}, c_0 = E(C_0))$

37 (16)

1 **partPSE_K^{HR}**

2 To derive partPSE via Cox's proportional hazards model, a log hazard model
3 without time-varying confounders is required, and we modified model (15) as

4
$$\log\left(\lambda_Y(t|A, C_{(0,K)}, M_{(1,K)})\right) = \log(\lambda_0(t)) + \alpha^Y C_0 + \beta^Y A + \sum_{h=1}^K \delta_h^Y M_h. \quad (17)$$

5 By equations (6), (9) and (17), the approximated log hazard function of counterfactual
6 outcome is given by

7
$$\log\left(\tilde{\lambda}_\psi(a_1, e_{(1,K)}; t)\right) \approx \log(\lambda_0(t)) + \beta^Y a_1 + \sum_{j=1}^K Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) \beta_j^M e_j$$

8
$$+ (\alpha^Y + \sum_{j=1}^K Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) \alpha_j^M) E(C_0) + \frac{1}{2} \sum_{j=1}^K Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) \sigma_{M,j}^2$$

9 where $Z_K^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) = \delta_K^Y$, $Z_j^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) = \delta_j^Y + \sum_{d=j+1}^K Z_d^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) \delta_{d,j}^M$. Derivation of the
10 above expression is in Appendix Section 4. Based on the result above, partPSE
11 incorporating with Cox's proportional hazards model in log HR scale (8) is

12
$$\text{partPSE}_K^{\text{HR}}(g, a_{(1)}^*, a_{(0)}^*)$$

13
$$= I_{(g=0)} \beta^Y (a_{(1)}^* - a_{(0)}^*) + I_{(g>0)} Z_g^0(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) \beta_g^M (a_{(1)}^* - a_{(0)}^*) \text{ for } g \in \{0, 1, 2, \dots, K\}.$$

14 (18)

15 The examples of $i\text{PSE}_K^{\text{HR}}(d, a_{(1)}^*, a_{(0)}^*)$ and $\text{partPSE}_K^{\text{HR}}(g, a_{(1)}^*, a_{(0)}^*)$ are shown in
16 Appendix Section 4.

17 Obviously, the estimator of $i\text{PSE}_K^{\text{HR}}$ is the same as that of $i\text{PSE}_K^{\text{HD}}$ by replacing
18 $\boldsymbol{\theta}_y^{\text{Aalen}}$ by $\boldsymbol{\theta}_y^{\text{Cox}}$. As a result, all properties, including the comparison with SEM
19 estimator and the relation between $i\text{PSE}_K^{\text{HD}}$ and $\text{partPSE}_K^{\text{HD}}$ which are discussed in
20 Section 3.2, are still applicable for $i\text{PSE}_K^{\text{HR}}$ and $\text{partPSE}_K^{\text{HR}}$.

21 **4. Asymptotic theorems**

22 For simplification, we set $a_{(1)}^*$ and $a_{(0)}^*$ as one and zero in Sections 4 and 5,
23 respectively. Based on the proposed estimators for PSEs in the previous section, the
24 following result shows the asymptotic properties about $i\text{PSE}_K^{\text{HD}}(d)$, $\text{partPSE}_K^{\text{HD}}(d)$,
25 $i\text{PSE}_K^{\text{HR}}(g)$, and $\text{partPSE}_K^{\text{HR}}(g)$ for each d and g . Since these estimators are the
26 functions of $\boldsymbol{\theta}$ and $\boldsymbol{\theta}_y^{\text{Aalen}}$ (or $\boldsymbol{\theta}_y^{\text{Cox}}$), these PSEs can be represented as

27
$$i\text{PSE}_K^{\text{HD}}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) = \{i\text{PSE}_K^{\text{HD}}(d) | d = 1, \dots, 2^K\},$$

28
$$\text{partPSE}_K^{\text{HD}}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}) = \{\text{partPSE}_K^{\text{HD}}(g) | g = 0, 1, \dots, K\},$$

29
$$i\text{PSE}_K^{\text{HR}}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) = \{i\text{PSE}_K^{\text{HR}}(d) | d = 1, \dots, 2^K\}, \text{ and}$$

30
$$\text{partPSE}_K^{\text{HR}}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}}) = \{\text{partPSE}_K^{\text{HR}}(g) | g = 0, 1, \dots, K\}.$$

31 We first provided a theorem to show the asymptotic distributions of PSE estimators on
32 Aalen's additive hazards model. As mentioned above, $\hat{\boldsymbol{\theta}}$ is the MLE and for $\boldsymbol{\theta}$,

1 $\widehat{\boldsymbol{\theta}}_y^{\text{Aalen}}$ the estimator via semiparametric estimating equation for $\boldsymbol{\theta}_y^{\text{Aalen}}$, and $\widehat{\boldsymbol{\theta}}_y^{\text{Cox}}$ the
2 partial likelihood estimator for $\boldsymbol{\theta}_y^{\text{Cox}}$. We denote the true value of $(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}}, \boldsymbol{\theta}_y^{\text{Cox}})$ by
3 $(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}}, \boldsymbol{\theta}_{y0}^{\text{Cox}})$. Under causal assumptions in Section 2, we have *Theorems 3* and 4
4 for the asymptotic distributions.

5

6 *Theorem 3.*

7 (1) Under *Assumptions 1* to 4, we have

$$8 \quad \sqrt{n} \left(iPSE_K^{HD}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Aalen}}) - iPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}}) \right) \xrightarrow{D} N(0, \boldsymbol{\Sigma}_{int}^{HD}),$$

9 where $\boldsymbol{\Sigma}_{int}^{HD} = \frac{\partial iPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T} \text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}}) \frac{\partial iPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})}$, and

10 (2) Under *Assumptions 1* to 6, we have

$$11 \quad \sqrt{n} \left(partPSE_K^{HD}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Aalen}}) - partPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}}) \right) \xrightarrow{D} N(0, \boldsymbol{\Sigma}_{part}^{HD})$$

12 where $\boldsymbol{\Sigma}_{part}^{HD} = \frac{\partial partPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T} \text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}}) \frac{\partial partPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})}$.

13

14 Here, $\frac{\partial iPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T}$, $\frac{\partial partPSE_K^{HD}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T}$, and $\text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Aalen}})$ are estimated by

15 $\frac{\partial iPSE_K^{HD}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T}$, $\frac{\partial partPSE_K^{HD}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Aalen}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Aalen}})^T}$ and $\widehat{\text{Cov}}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Aalen}})$. Similarly, the asymptotic

16 distributions of $iPSE_K^{HR}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})$ and $partPSE_K^{HR}(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})$ are derived in the
17 following theorem.

18

19 *Theorem 4.*

20 (1) Under *Assumptions 1* to 4 and rare outcome assumption, we have

$$21 \quad \sqrt{n} \left(iPSE_K^{HR}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Cox}}) - iPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}}) \right) \xrightarrow{D} N(0, \boldsymbol{\Sigma}_{int}^{HR}),$$

22 where $\boldsymbol{\Sigma}_{int}^{HR} = \frac{\partial iPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T} \text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}}) \frac{\partial iPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})}$, and

23 (2) Under *Assumptions 1* to 6 and rare outcome assumption, we have

$$24 \quad \sqrt{n} \left(partPSE_K^{HR}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Cox}}) - partPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}}) \right) \xrightarrow{D} N(0, \boldsymbol{\Sigma}_{part}^{HR})$$

25 where $\boldsymbol{\Sigma}_{part}^{HR} = \frac{\partial partPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T} \text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}}) \frac{\partial partPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})}$.

26

27 Similarly, $\frac{\partial iPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T}$, $\frac{\partial partPSE_K^{HR}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T}$, and $\text{Cov}(\boldsymbol{\theta}_0, \boldsymbol{\theta}_{y0}^{\text{Cox}})$ can be estimated by

28 $\frac{\partial iPSE_K^{HR}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T}$, $\frac{\partial partPSE_K^{HR}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Cox}})}{\partial(\boldsymbol{\theta}, \boldsymbol{\theta}_y^{\text{Cox}})^T}$ and $\widehat{\text{Cov}}(\widehat{\boldsymbol{\theta}}, \widehat{\boldsymbol{\theta}}_y^{\text{Cox}})$, respectively. The details of

29 *Theorems 3* and 4 can be found in Appendix Section 2.3.

30 5. Simulation

31 In this section, we conduct a simulation study to evaluate the performance of our
32 proposed models with particular sample sizes based on Cox's proportional hazards
33 model. The Aalen's additive hazards model can smoothly substitute Cox's proportional

1 hazards model in this simulation. Since iPSE and partPSE are the approaches based on
 2 two different assumptions, we consider two scenarios, with and without time-varying
 3 confounders, for evaluation.

4 In scenario A, we simulated the exposure variable (A), two baseline confounders
 5 (C_{01}, C_{02}), three mediators (M_1, M_2, M_3), and three corresponding time-varying
 6 confounders (C_1, C_2, C_3) under the models

$$\begin{aligned}
 & A \sim \text{Bernoulli}(0.2), C_{01}, C_{02} \sim \text{Bernoulli}(0.2), \\
 & C_1 = 0.5 + 0.5(A + C_{01} + C_{02}) + \varepsilon_{C1}, \\
 & M_1 = 0.5 + 0.5^2(A + C_{01} + C_{02}) + 0.25C_1 + \varepsilon_{M1}, \\
 & C_2 = 0.5 + 0.5^3(A + C_{01} + C_{02} + C_1 + M_1) + 0.25M_1 + \varepsilon_{C2}, \\
 & M_2 = 0.5 + 0.5^4(A + C_{01} + C_{02} + C_1 + M_1 + C_2) + 0.25C_2 + \varepsilon_{M2}, \\
 & C_3 = 0.5 + 0.5^5(A + C_{01} + C_{02} + C_1 + M_1 + C_2 + M_2) + 0.25M_2 + \varepsilon_{C3}, \text{ and} \\
 & M_3 = 0.5 + 0.5^6(A + C_{01} + C_{02} + C_1 + M_1 + C_2 + M_2 + C_3) + 0.25C_3 + \varepsilon_{M3},
 \end{aligned}$$

14 where $\varepsilon_{C1}, \varepsilon_{M1}, \varepsilon_{C2}, \varepsilon_{M2}, \varepsilon_{C3}$, and ε_{M3} follow a normal distribution with zero mean
 15 and standard deviation is 0.5. To simulate the survival times (Y) from Cox's
 16 proportional hazards model, we applied the inverse probability method into data
 17 generation (Bender, *et al.*, 2005), and the simulation procedure is shown as follows.
 18 The event times (T) are generated according to a Weibull distribution as

$$\begin{aligned}
 & T = -\log(u) / (0.01 \times e^{\mu_T}), u \sim \text{Uniform}(0,1) \text{ where} \\
 & \mu_T = 0.5 + 0.5(A + C_{01} + C_{02} + 0.2C_1 + 0.2M_1 + 0.4C_2 + 0.4M_2 + 0.8C_3 + 0.8M_3),
 \end{aligned}$$

21 The censoring times (C_T) are randomly drawn from an exponential distribution with a
 22 rate of 0.001. As a result, the observed survival times is defined as the minimum of T
 23 and C_T . Different from scenario A including time-varying confounders, scenario B aims
 24 to investigate the properties of partPSE, which assumes no time-varying confounders.
 25 Thus, we generated data without time-varying confounders in scenario B, and, the
 26 generative models are modified as follows:

$$\begin{aligned}
 & A \sim \text{Bernoulli}(0.2), C_{01}, C_{02} \sim \text{Bernoulli}(0.2), \\
 & M_1 = 0.5 + 0.5^2(A + C_{01} + C_{02}) + \varepsilon_{M1}, \\
 & M_2 = 0.5 + 0.5^4(A + C_{01} + C_{02} + M_1) + \varepsilon_{M2}, \text{ and} \\
 & M_3 = 0.5 + 0.5^6(A + C_{01} + C_{02} + M_1 + M_2) + \varepsilon_{M3}.
 \end{aligned}$$

31 Similarly, the event times in scenario B are also generated by

$$\begin{aligned}
 & T = -\log(u) / (0.01 \times e^{\mu_T}), u \sim \text{Uniform}(0,1), \text{ and} \\
 & \mu_T = 0.5 + 0.5(A + C_{01} + C_{02} + 0.2M_1 + 0.4M_2 + 0.8M_3).
 \end{aligned}$$

34 For both scenarios, with sample sizes $n = 1000$, we report the simulation results from
 35 1000 replicates in the next section.

36 The results of eight ($=2^3$) $iPSE_3^{HR}$ under scenario A are presented in Table 1, and
 37 we used bias, standard deviation (SD), root mean square error (RMSE), and coverage
 38 rate (CR) to measure the performance of point and interval estimates. We adopted the
 39 bootstrap approach for SD estimation instead of applying the asymptotic variance for

1 simplicity. This simulation includes three ordered mediators, and the effects of eight
2 different paths are estimated. As a result, the absolute value of the bias for each effect
3 less than 0.003, and the CRs are around 95%. While the CRs for the paths of
4 $A \rightarrow M_2 \rightarrow M_3 \rightarrow Y$ and $A \rightarrow M_1 \rightarrow M_2 \rightarrow M_3 \rightarrow Y$ are slightly away from 95%, the small
5 bias and RMSE of these effects reveal that the estimators are efficient. Additionally, the
6 true effect values of the two paths above are relatively small than the others, implying
7 that more samples are required for the paths with small effect sizes to increase accuracy.
8 Under scenario B, Table 2 shows the simulation result of four ($=3+1$) $partPSE_3^{HR}$. The
9 biases are close to zero, and the CRs are around 95%. The CR of $A \rightarrow M_3 \rightarrow Y$ in Table
10 2 also less than 95% due to the small effect.

11 To explore the asymptotic properties of the proposed estimators, we varied the
12 sample sizes for both scenarios in this section. The simulated data sets are generated
13 from the same models of scenarios A and B, and fifty different sample sizes uniformly
14 selected from the interval of (200, 10000) are considered in this simulation. Figures 3(a)
15 and 3(c) show the quantity of bias under different sample sizes for $iPSE_3^{HR}$ and
16 $partPSE_3^{HR}$, respectively. Figures 3(b) and 3(d) illustrate the patterns of SD when
17 sample sizes increase. Consequently, when the sample size increases, the bias and SD
18 in both approaches massively decreases. The result provides clear evidence that the
19 proposed estimators converge to the correct parameters in large sample size.

20 **6. Data application**

21 Epigenetics is a molecular process that influences the flow of information between
22 the underlying DNA sequence and variable gene expression patterns without altering
23 DNA sequences. DNA methylation is one of the critical epigenetic factors to regulate
24 gene expression during development and cell proliferation (Jaenisch and Bird, 2003).
25 Recently, the DNA-methylated regions have been studied extensively in cancer studies
26 (Hansen, *et al.*, 2011). While the correlation between DNA methylation and gene
27 expression in cancer has been reported (Spainhour, *et al.*, 2019), the causal mechanism
28 across genes remains to be studied. In this section, we used the proposed causal multi-
29 mediation analysis to explore the underlying causal mechanism in TCGA (The Cancer
30 Genome Atlas) database.

31 We chose 453 patients with lung cancer, 226 with adenocarcinoma and 227 with
32 squamous cell carcinoma, and all of the genomics data and patients' information were
33 downloaded from TCGA website. DNA methylation and gene expression were
34 measured in these patients using Illumina Human-Methylation 450K and Agilent gene
35 expression arrays, respectively. All genomic markers were measured on primary tumor
36 samples collected during surgery. From the pre-analysis of the association between the

1 methylation-expression pairs and the survival outcome, we identified that the
 2 methylation change in the gene CD109 can significantly affect the survival outcome.
 3 In the literature, DNA methylation of CD109 has a role in gastrointestinal cancer and
 4 colorectal cancer for poor survival (Shigaki, *et al.*, 2015; Yi, *et al.*, 2011). In this study,
 5 we illustrate our method by investigating the detailed mechanisms of CD109
 6 methylation influencing the survival outcome through gene expression in lung cancer
 7 patients.

8 Let DNA methylation of CD109 at cg06340118 as the exposure (A), survival as
 9 the outcome (Y), gene expression of CD109 as the third mediator (M_3). We further
 10 included another two gene expressions (SLC16A3, CLIC6) as (M_1 , M_2) based on the
 11 pre-selected methylation-expression pairs that affected survival. SLC16A3 and CLIC6
 12 have a function concerning ion channels and transporters that are a new class of
 13 membrane proteins aberrantly expressed in cancer (Lastraioli, *et al.*, 2015). To
 14 investigate the causal mechanism, we consider the causal structures as shown in Figure
 15 4. We applied our method to decompose the total effects into eight iPSEs and four
 16 partPSEs, separately. Since the genomic experiment usually does not include the time-
 17 varying confounders, we adopted the reduced version of iPSE without time-varying
 18 confounders as discussed in Section 2. We employed Aalen’s additive hazards model
 19 and Cox’s proportional hazards model for survival analyses. Patients’ age, gender,
 20 ethnicity, radiation therapy, cancer type, cancer stage, and smoking pack-years were
 21 adjusted as baseline confounders (C_0).

22 The result of PSE estimation is shown in Table 3. At 0.05 α -level, partial PSEs
 23 estimated by $partPSE_3^{HD}$ are all significant. In addition, the detailed decomposition
 24 estimated by $iPSE_3^{HD}$ reveals that the effect sizes of methylation through some
 25 pathways are relatively small. For example, $partPSE_3^{HD}(1)$, which is the effect first
 26 mediated by M_1 (that is $A \rightarrow M_1 Y$), is significant. $A \rightarrow M_1 Y$ can be decomposed into
 27 four paths, $A \rightarrow M_1 \rightarrow Y$, $A \rightarrow M_1 \rightarrow M_2 \rightarrow Y$, $A \rightarrow M_1 \rightarrow M_3 \rightarrow Y$, and
 28 $A \rightarrow M_1 \rightarrow M_2 \rightarrow M_3 \rightarrow Y$, and the result of $iPSE_3^{HD}$ shows that the significant effect of
 29 $A \rightarrow M_1 Y$ is mostly contributed by pathways $A \rightarrow M_1 \rightarrow Y$ and $A \rightarrow M_1 \rightarrow M_3 \rightarrow Y$. The
 30 result above reflects the utility of iPSE for comprehensively exploring the causal
 31 mechanism. Additionally, in agreement with the literature, the estimated direct effects
 32 of DNA methylation at cg06340118 in survival ($A \rightarrow Y$) significantly away from zero
 33 (Shigaki, *et al.*, 2015; Yi, *et al.*, 2011). Moreover, the effect of CD109 methylation at
 34 locus cg06340118 on survival time mediated through CD109 gene expression
 35 ($A \rightarrow M_3 \rightarrow Y$) are negative. The negative correlation between DNA methylation and
 36 gene expression among the promoter region has been a pattern commonly found by a
 37 pan-cancer analyses (Anastasiadi, *et al.*, 2018; Spainhour, *et al.*, 2019).

1 **7. Discussion**

2 Two significant contributions have been made by this study. First, we provide a
3 framework of causal multi-mediation analysis for an arbitrary number of ordered
4 mediators, including a general definition and two approaches for addressing the
5 difficulty of non-identifiability of traditional PSE. Second, we extend partPSE and iPSE
6 into the context of the survival analysis. Based on Aalen's additive hazards model and
7 Cox's proportional hazards model as well as normally distributed mediators, the
8 analytic forms of partPSE and iPSE can be obtained in both HD and HR scales. In
9 particular, when time-varying confounders are absence, the proposed iPSE is identical
10 to the SEM estimator.

11 Several limitations merit notice, and some should be improved in further studies.
12 First, the unmeasured confounding assumption is difficult to verified, and it is
13 challenging to collect all possible covariates comprehensively. Sensitivity analysis
14 technique is required in the future when a set of confounders are known in previous
15 literature but not collected in a study. Second, this framework may not be applicable to
16 settings with mediators truncated or semi-competed by the survival outcome, that could
17 cause biased or even undefined PSE estimation. In the future, it is worthy to extend
18 iPSE and partPSE into the analysis of truncated mediators. Third, although the causal
19 multi-mediation analysis can detail the mechanism of causal effects, the causal structure
20 including the order of mediators should be assumed based on domain knowledge.
21 Finally, a criterion for path selection or mediator selection is necessary to increase the
22 power of this method when the number of mediators is large.

23

24 **Sources of financial support:** This study is supported by the grant from Ministry of
25 Science and Technology in Taiwan (No. 108-2636-B-009 -001)

26

27 **Reference**

- 28 Albert, J.M., Cho, J.I., Liu, Y. and Nelson, S. (2019). Generalized causal mediation and path
29 analysis: Extensions and practical considerations. *Statistical methods in medical research*;
30 **28(6)**:1793-1807.
- 31 Anastasiadi, D., Esteve-Codina, A. and Piferrer, F. (2018). Consistent inverse correlation
32 between DNA methylation of the first intron and gene expression across tissues and species.
33 *Epigenetics & chromatin*; **11(1)**:37.
- 34 Avin, C., Shpitser, I. and Pearl, J. (2005). Identifiability of path-specific effects. *Department of*
35 *Statistics, UCLA*.

- 1 Bender, R., Augustin, T. and Blettner, M. (2005). Generating survival times to simulate Cox
2 proportional hazards models. *Statistics in medicine*; **24(11)**:1713-1723.
- 3 Cho, S.H. and Huang, Y.T. (2019). Mediation analysis with causally ordered mediators using
4 Cox proportional hazards model. *Statistics in medicine*; **38(9)**:1566-1581.
- 5 Daniel, R., De Stavola, B., Cousens, S. and Vansteelandt, S. (2015). Causal mediation analysis
6 with multiple mediators. *Biometrics*; **71(1)**:1-14.
- 7 Didelez, V., Dawid, P. and Geneletti, S. (2012). Direct and indirect effects of sequential
8 treatments. *arXiv preprint arXiv:1206.6840*.
- 9 Fasanelli, F., Giraudo, M.T., Ricceri, F., Valeri, L. and Zugna, D. (2019). Marginal Time-
10 Dependent Causal Effects in Mediation Analysis With Survival Data. *American journal of
11 epidemiology*; **188(5)**:967-974.
- 12 Geneletti, S. (2007). Identifying direct and indirect effects in a non-counterfactual framework.
13 *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*; **69(2)**:199-215.
- 14 Hansen, K.D., Timp, W., Bravo, H.C., Sabunciyar, S., Langmead, B., McDonald, O.G., Wen,
15 B., Wu, H., Liu, Y. and Diep, D. (2011). Increased methylation variation in epigenetic
16 domains across cancer types. *Nature genetics*; **43(8)**:768.
- 17 Huang, Y.-T. and Yang, H.-I. (2017). Causal Mediation Analysis of Survival Outcome with
18 Multiple Mediators. *Epidemiology*; **28(3)**:370-378.
- 19 Huang, Y.T. and Cai, T. (2015). Mediation analysis for survival data using semiparametric
20 probit models. *Biometrics*.
- 21 Jaenisch, R. and Bird, A. (2003). Epigenetic regulation of gene expression: how the genome
22 integrates intrinsic and environmental signals. *Nature genetics*; **33(3s)**:245.
- 23 Lange, T. and Hansen, J.V. (2011). Direct and indirect effects in a survival context.
24 *Epidemiology*; **22(4)**:575-581.
- 25 Lastraioli, E., Iorio, J. and Arcangeli, A. (2015). Ion channel expression as promising cancer
26 biomarker. *Biochimica et Biophysica Acta (BBA)-Biomembranes*; **1848(10)**:2685-2702.
- 27 Lin, D. and Ying, Z. (1994). Semiparametric analysis of the additive risk model. *Biometrika*;
28 **81(1)**:61-71.
- 29 Lin, S.-H. and Vanderweele, T. (2017). Interventional Approach for Path-Specific Effects.
30 *Journal of Causal Inference*; **5(1)**.
- 31 Lin, S.H., Young, J., Logan, R., Tchetgen Tchetgen, E.J. and Vanderweele, T.J. (2017).
32 Parametric Mediation g-Formula Approach to Mediation Analysis with Time-varying
33 Exposures, Mediators, and Confounders. *Epidemiology*; **28(2)**:266-274.
- 34 Lin, S.H., Young, J.G., Logan, R. and Vanderweele, T.J. (2017). Mediation analysis for a
35 survival outcome with time-varying exposures, mediators, and confounders. *Stat Med*;
36 **36(26)**:4153-4166.
- 37 Loh, W.W., Moerkerke, B., Loeys, T. and Vansteelandt, S. (2019). Interventional Effect Models
38 for Multiple Mediators. *arXiv preprint arXiv:1907.08415*.

- 1 Moreno-Betancur, M. and Carlin, J.B. (2018). Understanding interventional effects: a more
2 natural approach to mediation analysis? *Epidemiology*; **29(5)**:614-617.
- 3 Moreno-Betancur, M., Moran, P., Becker, D., Patton, G. and Carlin, J.B. (2019). Defining
4 mediation effects for multiple mediators using the concept of the target randomized trial.
5 *arXiv preprint arXiv:1907.06734*.
- 6 Pearl, J. (2009). Causal inference in statistics: An overview. *Statistics Surveys*; **3**:96-146.
- 7 Robins, J. (1986). A new approach to causal inference in mortality studies with a sustained
8 exposure period—application to control of the healthy worker survivor effect. *Mathematical*
9 *Modelling*; **7(9)**:1393-1512.
- 10 Robins, J.M. and Greenland, S. (1992). Identifiability and exchangeability for direct and
11 indirect effects. *Epidemiology*:143-155.
- 12 Shigaki, H., Baba, Y., Harada, K., Yoshida, N., Watanabe, M. and Baba, H. (2015). Epigenetic
13 changes in gastrointestinal cancers. *Journal of Cancer Metastasis and Treatment*; **1(3)**:113-
14 113.
- 15 Spainhour, J.C., Lim, H.S., Yi, S.V. and Qiu, P. (2019). Correlation patterns between DNA
16 methylation and gene expression in The Cancer Genome Atlas. *Cancer informatics*;
17 **18**:1176935119828776.
- 18 Steen, J., Loeys, T., Moerkerke, B. and Vansteelandt, S. (2017). Flexible mediation analysis
19 with multiple mediators. *American journal of epidemiology*; **186(2)**:184-193.
- 20 Taguri, M., Featherstone, J. and Cheng, J. (2015). Causal mediation analysis with multiple
21 causally non-ordered mediators. *Statistical methods in medical research*:0962280215615899.
- 22 Tchetgen, E.J.T. and Shpitser, I. (2012). Semiparametric theory for causal mediation analysis:
23 efficiency bounds, multiple robustness and sensitivity analysis. *The Annals of Statistics*;
24 **40(3)**:1816-1845.
- 25 Vanderweele, T. and Vansteelandt, S. (2009). Conceptual issues concerning mediation,
26 interventions and composition. *Statistics and its Interface*; **2**:457-468.
- 27 Vanderweele, T.J. (2009). Concerning the consistency assumption in causal inference.
28 *Epidemiology*; **20(6)**:880-883.
- 29 Vanderweele, T.J. (2011). Causal mediation analysis with survival data. *Epidemiology*
30 *(Cambridge, Mass.)*; **22(4)**:582.
- 31 Vanderweele, T.J. and Tchetgen Tchetgen, E. (2017). Mediation Analysis with Time-Varying
32 Exposures and Mediators. *Journal of the Royal Statistical Society: Series B (Statistical*
33 *Methodology)*.
- 34 Vanderweele, T.J. and Vansteelandt, S. (2014). Mediation Analysis with Multiple Mediators.
35 *Epidemiol Method*; **2(1)**:95-115.
- 36 Vanderweele, T.J., Vansteelandt, S. and Robins, J.M. (2014). Effect decomposition in the
37 presence of an exposure-induced mediator-outcome confounder. *Epidemiology*; **25(2)**:300-
38 306.

1 Vansteelandt, S. and Daniel, R.M. (2017). Interventional effects for mediation analysis with
2 multiple mediators. *Epidemiology (Cambridge, Mass.)*; **28(2)**:258.

3 Wang, W., Nelson, S. and Albert, J.M. (2013). Estimation of causal mediation effects for a
4 dichotomous outcome in multiple-mediator models using the mediation formula. *Statistics in
5 medicine*; **32(24)**:4211-4228.

6 Yi, J.M., Dhir, M., Van Neste, L., Downing, S.R., Jeschke, J., Glöckner, S.C., De Freitas
7 Calmon, M., Hooker, C.M., Funes, J.M. and Boshoff, C. (2011). Genomic and epigenomic
8 integration identifies a prognostic signature in colon cancer. *Clinical Cancer Research*;
9 **17(6)**:1535-1545.

10 Yu, Q., Wu, X., Li, B. and Scribner, R.A. (2019). Multiple mediation analysis with survival
11 outcomes: With an application to explore racial disparity in breast cancer survival. *Statistics
12 in medicine*; **38(3)**:398-412.

13 Zheng, W. and Van Der Laan, M.J. (2012). Causal mediation in a survival setting with time-
14 dependent mediators.

15
16

1

	<i>Generalized linear model</i>	<i>Survival model</i>
3. Complete (full or finest) decomposition (Number of decomposed paths = 2^K)	3.1 Sensitivity analysis - Daniel, R. M., et al. (2015). <i>Biometrics</i> * - Albert, J. M., Cho, J. I., Liu, Y., & Nelson, S. (2019) <i>Statistical methods in medical research</i> ** 3.2 Complete interventional approach - Lin, S. H., & VanderWeele, T. (2017). <i>Journal of Causal Inference</i> *	3.2 Complete interventional approach ✓ The proposed methods ($iPSE_K^{HD}$, $iPSE_K^{HR}$) §
2. Partial decomposition (Number of decomposed paths < 2^K)	2.1 Partial parallel decomposition (Number of decomposed paths = $K + 1$) - Wang, W., Nelson, S., & Albert, J. M. (2013). <i>Statistics in medicine</i> § - Taguri, M., Featherstone, J., & Cheng, J. (2018). <i>Statistical methods in medical research</i> § 2.2 Partial sequential decomposition (Number of decomposed paths = $K + 1$) - Steen, Johan, et al. (2017). <i>American journal of epidemiology</i> * - VanderWeele, T. J., Vansteelandt, S., & Robins, J. M. (2014). <i>Epidemiology</i> * 2.3 Partial unstructured decomposition (Number of decomposed paths = $K + 2$) - Vansteelandt, S., & Daniel, R. M. (2017). <i>Epidemiology</i> § - Loh, Wen Wei, et al. (2019). <i>arXiv preprint</i> § - Moreno-Betancur, M., et al. (2019). <i>arXiv preprint</i> §	2.1 Partial parallel decomposition (Number of decomposed paths = $K + 1$) - Yu, Qingzhao, et al. (2019). <i>Statistics in medicine</i> § 2.3 Partial sequential decomposition (Number of decomposed paths = $K + 1$) - Huang, Y. T., & Cai, T. (2016). <i>Biometrics</i> * - Huang, Y. T., & Yang, H. I. (2017). <i>Epidemiology</i> * - Cho, S. H., & Huang, Y. T. (2019). <i>Statistics in medicine</i> † ✓ The proposed methods ($partPSE_K^{HD}$, $partPSE_K^{HR}$) §
1. Two-way decomposition (Number of decomposed paths = 2, i.e. direct and indirect effects)	- VanderWeele, T., & Vansteelandt, S. (2014). <i>Epidemiologic methods</i> - VanderWeele, T. J., Vansteelandt, S., & Robins, J. M. (2014). <i>Epidemiology</i>	- Fasanelli, Francesca, et al. (2019) <i>American journal of epidemiology</i>

* Applicable for $K = 2$ mediators; ** Applicable for two ordered stage of mediators and arbitrary number of parallel mediators per stage
 † Applicable for $K = 3$ mediators
 § Applicable for an arbitrary number of mediators


2

3

Figure 1. Literature review of causal multi-mediation analysis with K mediators.

4

5



6


7

Figure 2. The causal relationship among all variables is demonstrated by a direct acyclic graph (DAG). A , $M_{(1,K)}$, Y , C_0 , and $C_{(1,K)}$, denote the exposure, the mediators, the outcome, the baseline confounders, and the time-varying confounders, respectively.

8


9

10



1
2
3
4
5
6
7
8

Figure 3. The scatter plots of bias and standard deviation across fifty different sample sizes uniformly selected from the interval of (200, 10000). (a) and (b) are the plots of bias and standard deviation (SD) for $iPSE_3^{HR}$ based on scenarios A, respectively. (c) and (d) are the plots of bias and SD for $partPSE_3^{HR}$ based on scenarios B, respectively. The smoothing curves are done by locally weighted regression, controlling the degree of smoothing at 0.6.



9
10
11
12
13

Figure 4. The causal diagram of DNA methylation of CD109, gene expression on different genes (including SLC16A3, CLIC6, and CD109), and lung cancer.

1 **Table 1.** Simulation result under the scenario A for $iPSE_3^{HR}$

Path*	True value	Bias	SD	RMSE	CR
A→Y	0.609	0.00300	0.11594	0.11598	95.3
A→M ₁ →Y	0.062	0.00082	0.03613	0.03614	94.8
A→M ₂ →Y	0.042	0.00088	0.01985	0.01987	95.1
A→M ₁ →M ₂ →Y	0.009	-0.0001	0.00566	0.00566	95.0
A→M ₃ →Y	0.016	0.00002	0.01768	0.01768	95.0
A→M ₁ →M ₃ →Y	0.003	0.00013	0.00664	0.00665	95.6
A→M ₂ →M ₃ →Y	0.001	0.00001	0.00273	0.00273	93.9
A→M ₁ →M ₂ →M ₃ →Y	0.0002	0.00001	0.00064	0.00064	94.4

2 *Both baseline confounders and time-varying confounders are present in each path.
 3 Abbreviation: SD, standard deviation; RMSE, root mean square error; CR, coverage rate.

4

5 **Table 2.** Simulation result under the scenario B for $partPSE_3^{HR}$

Path*	True value	Bias	SD	RMSE	CR
A→Y	0.50000	0.00519	0.13789	0.13799	95.2
A→M ₁ Y**	0.02979	-0.00066	0.03134	0.03135	95.1
A→M ₂ Y**	0.01289	-0.00009	0.01217	0.01217	94.8
A→M ₃ →Y	0.00625	0.00033	0.01707	0.01707	93.8

6 *Only baseline confounders are present in each path.
 7 ** $(A \rightarrow M_2 Y) = (A \rightarrow M_2 \rightarrow Y) + (A \rightarrow M_2 \rightarrow M_3 \rightarrow Y)$; $(A \rightarrow M_1 Y)$ follows the same definition.
 8 Abbreviation: SD, standard deviation; RMSE, root mean square error; CR, coverage rate.

9

10 **Table 3.** Effect decomposition of CD109 methylation (A) on lung cancer (Y) through
 11 the gene expression of SLC16A3 (M₁), CLIC6 (M₂), and CD109 (M₃).

Path	Aalen's additive hazards model (in HD scale)				Cox's proportional hazards model (in log HR scale)			
	$iPSE_3^{HD}$		$partPSE_3^{HD}$		$iPSE_3^{HR}$		$partPSE_3^{HR}$	
	PSE (SD)	P value	PSE (SD)	P value	PSE (SD)	P value	PSE (SD)	P value
A→Y	0.061 (0.002)	0.002*	0.061 (0.020)	0.002*	0.397 (0.128)	0.002*	0.397 (0.128)	0.002*
A→M ₁ →Y	-0.015 (0.006)	0.016*			-0.095 (0.037)	0.011*		
A→M ₁ →M ₃ →Y	-0.002 (0.006)	0.057	-0.018 (0.007)	0.008*	-0.018 (0.028)	0.039*	-0.113 (0.040)	0.005*
A→M ₁ →M ₂ →Y	-0.0001 (0.001)	0.927			-5×10^{-4} (0.005)	0.922		
A→M ₁ →M ₂ →M ₃ →Y	-8×10^{-6} (0.013)	0.933			-1×10^{-4} (0.077)	0.929		
A→M ₂ →Y	-0.013 (0.001)	0.018*	-0.015 (0.006)	0.013*	-0.075 (0.009)	0.009*	-0.085 (0.031)	0.006*
A→M ₂ →M ₃ →Y	-0.001 (0.001)	0.108			-0.01 (0.006)	0.082		
A→M ₃ →Y	-0.029 (0.0001)	0.024*	-0.029 (0.013)	0.024*	-0.197 (0.001)	0.009*	-0.199 (0.077)	0.009*

12 * P value < 0.05
 13 Abbreviation: PSE, path-specific effect; HD, hazard difference; HR, hazard ratio; SD, standard deviation.